ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma

Shen, Yefeng; Wang, Shaochun; Wu, Yuanzhou*南方医科大学
Cells2022-8DOI: 10.3390/cells11152399
5被引9阅读
引用收藏
分享

摘要

N6-methyladenosine (m6A) and long non-coding RNA (lncRNA) have been associated with cancer prognosis and the effect of immunotherapy. However, the roles of m6A-related lncRNAs in the prognosis and immunotherapy in lung adenocarcinoma (LUAD) patients remain unclear. We evaluated the m6A modification patterns of 695 samples based on m6A regulators, and prognostic m6A-related lncRNAs were identified via a weighted gene co-expression network analysis. Twelve abnormal m6A regulators and nine prognostic lncRNAs were identified. The tumor microenvironment cell-infiltrating characteristics of three m6A-related lncRNA clusters were highly consistent with the three immune phenotypes of tumors, including immune-excluded, immune-inflamed and immune-desert phenotypes. The lncRNA score system was established, and high lncRNA score patients were associated with better overall survival. The lncRNA score was correlated with the expression of the immune checkpoints. Two immunotherapy cohorts supported that the high lncRNA score enhanced the response to anti-PD-1/L1 immunotherapy and was remarkably correlated with the inflamed immune phenotype, showing significant therapeutic advantages and clinical benefits. Furthermore, the patients with high lncRNA scores were more sensitive to erlotinib and axitinib. The lncRNA score was associated with the expression of miRNA and the regulation of post-transcription. We constructed an applied lncRNA score-system to identify eligible LUAD patients for immunotherapy and predict the sensitivity to chemotherapeutic drugs.

学科与关键词

关键词
lung adenocarcinomam6AlncRNA scoreimmune checkpointsimmunotherapy
相关
加载中…
  • Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma
    Zhao, Jianhui; Lin, Xi; Zhuang, Jinman; He, Fei*Frontiers in Genetics, 2021, 12: 714697.被引 15
  • N6-Methyladenosine (m6A)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma
    Zhou, Yang; Guan, Xuhui; Wang, Shuncong; Sun, Huanhuan*; Ma, Haiqing*Journal of Oncology, 2022, 2022: 5240611.
  • Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma
    Weng, Chengyin; Wang, Lina; Liu, Guolong*; Guan, Mingmei*; Lu, Lin*Frontiers in Oncology, 2021, 11: 763027.被引 12
查看全部 →

发表信息

论文状态
公开发表
期刊
Cells
发表日期
2022-08
卷期
第 11 卷, 第 15 期
页码
2399
DOI
10.3390/cells11152399
期刊等级
3区
成果收录
SCIE
资助标注
Oversea Study Program of Guangzhou Elite Project

作者

  • S

    Shen, Yefeng (第一作者)

    southern med univ

  • W

    Wang, Shaochun

查看全部 3 位作者收起作者
  • W

    Wu, Yuanzhou (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417